Free Trial
NYSE:ZYME

Zymeworks 5/8/2025 Earnings Report

Zymeworks logo
$11.49 -0.45 (-3.77%)
Closing price 03:59 PM Eastern
Extended Trading
$11.48 -0.01 (-0.09%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.15
One Year Ago EPS
-$0.42

Zymeworks Revenue Results

Actual Revenue
$27.11 million
Expected Revenue
$20.65 million
Beat/Miss
Beat by +$6.46 million
YoY Revenue Growth
+170.30%

Zymeworks Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zymeworks' next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules.

Conference Call Resources

Zymeworks Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Zymeworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zymeworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zymeworks and other key companies, straight to your email.

About Zymeworks

Zymeworks (NYSE:ZYME), a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

View Zymeworks Profile

More Earnings Resources from MarketBeat